GLP-1 receptor agonist therapy reduced atrial fibrillation recurrence following catheter ablation compared to no GLP-1 RA use (HR 0.53, 95% CI 0.38-0.72; 12-month rate 28.6% vs 32.9%).
Meta-Analysis (n=695)
Does GLP-1 RA therapy reduce atrial fibrillation recurrence in adult patients undergoing catheter ablation for AF?
Peri- or post-ablation use of GLP-1 receptor agonists is associated with a significantly reduced risk of atrial fibrillation recurrence at 12 months.
Effect estimate: RR 0.82 (95% CI 0.76-0.90)
Absolute Event Rate: 28.6% vs 32.9%
ABSTRACT Background Among patients undergoing catheter ablation for atrial fibrillation (AF), it remains uncertain whether peri‐ or post‐ablation use of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) reduces AF recurrence. Objectives We conducted a meta‐analysis of observational studies and randomized controlled trials comparing GLP‐1 RA therapy versus no GLP‐1 RA use on AF recurrence following ablation. Methods We systematically searched PubMed, Scopus, Web of Science, and Embase for adult randomized and observational studies. Random‐effects models generated risk ratios (RRs), and heterogeneity was assessed via I 2 . Time‐to‐event outcomes were synthesized using reconstructed individual patient data from Kaplan–Meier curves. Results Six studies met the inclusion criteria, with four contributing data for Kaplan–Meier curve reconstruction and five included in the hazard ratio (HR) meta‐analysis. Across four studies ( n = 695; GLP‐1 RA = 295; control = 400), pooled Kaplan–Meier curves showed a lower risk of AF recurrence with GLP‐1 RA therapy (HR 0.53, 95% confidence interval CI: 0.38–0.72), with a restricted mean survival time (RMST) advantage of 1.02 months. A random‐effects meta‐analysis of five studies confirmed this benefit (HR 0.78, 95% CI: 0.61–0.99; I 2 = 75%). Pairwise analyses at 12 months demonstrated fewer AF recurrences with GLP‐1 RAs (28.6% vs. 32.9%; RR 0.82, 95% CI: 0.76–0.90; I 2 = 46.9%). Conclusion GLP‐1 RA therapy was associated with reduced AF recurrence after ablation, but methodological limitations warrant cautious interpretation. Prospective randomized trials are needed to confirm this potential benefit.
Shubietah et al. (Sat,) conducted a meta-analysis in Atrial fibrillation undergoing catheter ablation (n=695). GLP-1 receptor agonists vs. No GLP-1 RA use was evaluated on Atrial fibrillation recurrence (RR 0.82, 95% CI 0.76-0.90). GLP-1 receptor agonist therapy reduced atrial fibrillation recurrence following catheter ablation compared to no GLP-1 RA use (HR 0.53, 95% CI 0.38-0.72; 12-month rate 28.6% vs 32.9%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: